Macular degeneration trials in Armenia

1 trial · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 2Taking people
  A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

  Where

  Yerevan

  Age

  55 years to 64 years

  People

  110 worldwide

  Run by

  Galimedix Therapeutics Inc

  See details and how to joinNCT06659549 · EU 2024-519128-26-00